Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
J Tradit Chin Med. 2018 Oct;38(5):705-713.
To investigate the mechanism underlying the action of Weipixiao (WPX) in a rat's model with ameliorating gastric precancerous lesions (GPL).
HPLC analysis was performed to identify the chemical constituents of WPX preparation. Sprague- Dawley rats were randomly assigned into control group, model group, vitacoenzyme group, high-dose WPX group (H-WPX), medium-dose WPX group (M-WPX) and low-dose WPX group (L-WPX). After modeling, the treated rats were administrated WPX or vitacoenzyme intragastrically for consecutive 10 weeks. Gene and protein expressions of GSK3¦Â, C-myc, Cylin E were evaluated by quantitative real-time reverse transcription-polymerase chain reaction (RT-qPCR) and immunohistochemistry, respectively.
WPX could efficiently attenuate the pathological alterations of ""non-progressive GPL"" in rats. As expected, mRNA and protein levels of C-myc and Cylin E were up-regulated in model rats, while GSK3¦Â expression down-regulated (P < 0.01). WPX treatment, especially at low dose, could significantly down-regulate the mRNA as well as protein levels of C-myc, and could lead to remarkable up-regulation of mRNA and protein levels of GSK3¦Â in GPL rats (P < 0.05). However, no significant changes were observed in WPX-treated rats.
Our findings suggested that WPX-mediated attenuation of GPL pathological alterations might be due to its regulatory effect on the expressions of GSK3¦Â and C-myc, and on the dysregulation of Wnt/GSK3¦Â pathway.
研究胃痞消（WPX）改善胃癌前病变（GPL）大鼠模型作用的机制。
采用高效液相色谱法分析 WPX 制剂的化学成分。将 Sprague-Dawley 大鼠随机分为对照组、模型组、维酶素组、高剂量 WPX 组（H-WPX）、中剂量 WPX 组（M-WPX）和低剂量 WPX 组（L-WPX）。建模后，连续 10 周灌胃 WPX 或维酶素。采用实时荧光定量逆转录聚合酶链反应（RT-qPCR）和免疫组化法分别检测 GSK3¦Â、C-myc、Cylin E 的基因和蛋白表达。
WPX 能有效减轻大鼠“非进展性 GPL”的病理改变。如预期的那样，模型大鼠的 C-myc 和 Cylin E mRNA 和蛋白水平上调，而 GSK3¦Â 表达下调（P<0.01）。WPX 治疗，特别是低剂量组，可显著下调 GPL 大鼠的 C-myc mRNA 及蛋白水平，并可显著上调 GSK3¦Â 的 mRNA 及蛋白水平（P<0.05）。然而，WPX 治疗组未见明显变化。
我们的研究结果表明，WPX 减轻 GPL 病理改变可能与其对 GSK3¦Â 和 C-myc 表达的调节作用以及 Wnt/GSK3¦Â 通路的失调有关。
